Skip to main content
. 2023 Jun 3;53(7):547–561. doi: 10.1093/jjco/hyad052

Figure 2.

Figure 2

Breakdown of frequency and types of major resistance mechanisms to first-line (A) and later-line (B) osimertinib treatment based on previous reports (53–61). Note: different molecular aberrations might have been identified in the same patient. Abbreviations: amp., amplification; mut., mutation.